• DHA in Hippocampal Lipid Assay Design

  2026-09-11

  Discover how Docosahexaenoic Acid (DHA) can be evaluated through a region-resolved assay framework linking hippocampal lipid metabolism, synaptic structure, and cognition. This article translates spatial metabolomics findings into practical decisions for neuroprotection research without overstating preclinical evidence.

• AP-2α, MGMT, and Temozolomide Resistance

  2026-09-10

  The reference study defines AP-2α as a transcriptional suppressor of MGMT in recurrent glioblastoma and links loss of this control to temozolomide resistance. Its combination of promoter-mapping assays, resistant glioma models, DNA-damage measurements, and intracranial validation provides a mechanistic framework for studying MGMT-directed sensitization.

• EZ Cap™ Cas9 mRNA (m1Ψ): A Timing Framework

  2026-09-10

  EZ Cap™ Cas9 mRNA (m1Ψ) combines Cap1 capping, m1Ψ modification, and poly(A) tailing for controlled Cas9 expression. This article explains how mRNA localization, exposure duration, and assay design shape CRISPR-Cas9 genome editing results.

• EGLN3 in Pulmonary Vascular Remodeling and Dysfunction

  2026-09-09

  Deng et al. identify EGLN3 as a hypoxia-responsive driver of pulmonary vascular endothelial dysfunction, linking JUN-dependent transcription to HUR-mediated EGFR mRNA stabilization and downstream PI3K/AKT and MAPK signaling. The study combines patient and animal evidence with endothelial gain- and loss-of-function models, providing a mechanistic framework for interpreting EGLN3 as a potential pulmonary hypertension target.

• Cell Counting Kit-8 (CCK-8) for ccRCC Assays

  2026-09-09

  Use CCK8 to convert viable-cell metabolism into a practical, scalable readout for ccRCC proliferation and treatment-response studies. This guide connects WST-8 assay design with the ISG15–IL6/JAK2/STAT3 findings reported in recent renal cancer research, while emphasizing controls, optimization, and orthogonal validation.

• Fulvestrant (ICI 182,780) Workflow Guide

  2026-09-08

  Build reliable ERα degradation, MDM2 protein degradation, and chemotherapy-sensitization assays with Fulvestrant (ICI 182,780). This practical guide connects breast cancer workflows with an immune and endoplasmic-reticulum-stress model while clearly separating established findings from exploratory assay extensions.

• Phytol Assay Design: RXR, GABA, and Polymer Insight

  2026-09-08

  Phytol is more than an RXR ligand: its isomeric composition, hydrophobic formulation, metabolism, and GABAergic activity all shape experimental interpretation. This guide combines receptor pharmacology with a carefully bounded lesson from bottlebrush polymer self-assembly to improve assay design and decision-making.

• Myriocin and the SPTLC2–Ceramide Axis

  2026-09-07

  Myriocin offers translational researchers a precise pharmacologic entry point into serine palmitoyltransferase biology. When integrated with recent evidence linking SPTLC2-regulated de novo ceramide synthesis to post-infarction ventricular remodeling, it becomes more than a pathway inhibitor: it is a tool for testing metabolic causality across cardiac, oncology, and immunology models.

• Cell Counting Kit-8 for Translational Assays

  2026-09-07

  Cell Counting Kit-8 (CCK-8) converts viable-cell dehydrogenase activity into a convenient, water-soluble colorimetric readout for proliferation, viability, and cytotoxicity studies. This guide shows how to apply cck8 in growth-factor signaling research, including PDGF-C and anti-VEGF-refractory models, while avoiding common interpretation and optimization errors.

• HyperScribe T7 High Yield Cy3 RNA Labeling Kit Plus

  2026-09-05

  The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus provides a defined in vitro transcription workflow for producing randomly Cy3-modified RNA probes from a compatible T7 template. It is intended for research applications such as in situ hybridization, Northern blot hybridization, and fluorescence-based detection, and should not be used for diagnostic, clinical, or therapeutic purposes.

• Gepotidacin: A Topology-First Research Framework

  2026-09-04

  Gepotidacin (GSK2140944) offers a distinctive model for studying bacterial topoisomerase biology and resistance. This article connects DNA-topology readouts, cellular phenotypes, and lessons from novobiocin derivative research to improve assay interpretation.

• Cucurbitacin I (JSI-124) STAT3 Assay Workflows

  2026-09-04

  Build mechanism-led cancer experiments with Cucurbitacin I, from rapid phospho-STAT3 validation to apoptosis, invasion, chemosensitivity, and xenograft studies. The workflow also shows how multicellular assay logic from a human SAN-plexus assembloid study can improve experimental controls without implying cross-domain drug efficacy.

• CA-074: Reading Cathepsin B Assays in Context

  2026-09-03

  CA-074 is a selective cathepsin B inhibitor whose biological meaning depends on substrate, pH, tissue matrix, and orthogonal validation. This article uses barley senescence research to show how to distinguish cathepsin B contribution from broader cysteine-protease activity across cancer, neurodegeneration, and immune studies.

• MCC950 sodium: NLRP3 Workflow for Neuroinflammation

  2026-09-03

  MCC950 sodium enables precise interrogation of NLRP3-driven IL-1β signaling across macrophage and neuroinflammation workflows. This guide translates its nanomolar potency into practical assay design, including a spinal-cord morphine-tolerance model and troubleshooting strategies that distinguish pathway specificity from general cytotoxicity.

• Halazone and Sodium-Current Inactivation

  2026-09-02

  A voltage-clamp study in frog myelinated nerve fibers found that Halazone and hypochlorous acid strongly disrupted sodium-current inactivation, whereas several other oxidants produced mainly voltage shifts. The comparative reagent design challenged a methionine-centered explanation and raised membrane-lipid modification as a plausible, but unproven, mechanism.

8457 records 1/564 page Next 12345 下5页 Last page